Mural Oncology plc
MURA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MURA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Sep 30, 2025.
Tracking 1 pipeline candidate · 3 clinical trials for Mural Oncology plc.
Run Mural Oncology plc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Mural Oncology plc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
9.9 months
D/E 0.19
Lead: Phase 3
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Governance
Frequently asked questions
What is Mural Oncology plc's lead drug candidate?
Mural Oncology plc's most advanced tracked candidate is nemvaleukin alfa (Phase 3) for Cutaneous Melanoma.
Who is the CEO of Mural Oncology plc?
Corporate Governance Committee is the chief executive officer of Mural Oncology plc (MURA).
What therapeutic areas does Mural Oncology plc focus on?
Mural Oncology plc develops therapies across Oncology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.